Alligator Bioscience AB (0RK9)
LSE 
Summary
0RK9 Chart
Alligator Bioscience AB Dividends
Alligator Bioscience AB Earnings
| 9 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
| 23 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | - Cons. EPS | - EPS |
| 24 Oct 2024 Date | | - Cons. EPS | - EPS |
| 11 Jul 2024 Date | | - Cons. EPS | - EPS |
| 9 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
| 23 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | - Cons. EPS | - EPS |
| 24 Oct 2024 Date | | - Cons. EPS | - EPS |
| 11 Jul 2024 Date | | - Cons. EPS | - EPS |
Alligator Bioscience AB (0RK9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Alligator Bioscience AB ever had a stock split?
Alligator Bioscience AB Profile
| Biotechnology Industry | Healthcare Sector | - CEO | LSE Exchange | SE0000767188 ISIN |
| Sweden Country | 47 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alligator Bioscience AB, a public biotechnology company based in Sweden, specializes in the development of antibody-based pharmaceuticals for cancer treatment. With a focus on research, the company has fostered a strong pipeline of products, primarily aimed at treating solid metastatic tumors and various forms of cancer. Leveraging its proprietary technology platforms, Alligator Bioscience strives to innovate in the field of immunotherapy and antibody development. Founded in 2000 and headquartered in Lund, Sweden, the company has established several key collaborations and out-licensing agreements with prominent industry partners, demonstrating its commitment to advancing cancer treatment through cutting-edge biotechnological research.
Products and Services
Mitazalimab: This stimulatory antibody specifically targets CD40 and is currently in phase 2 clinical trials. It is being developed for the treatment of solid metastatic tumors, including pancreatic cancer, showcasing Alligator Bioscience’s dedication to addressing hard-to-treat cancers.
ATOR-4066: A tumor-directed bispecific antibody, ATOR-4066 is in the preclinical stage of development. Utilizing the Neo-X-Prime technology platform, it represents the company’s innovative approach to cancer immunotherapy, highlighting its potential in treating various cancers.
ALG.APV-527: Currently in phase 1 clinical trial, ALG.APV-527 is a bispecific antibody that simultaneously targets the 4-1BB and 5T4 molecules. This approach illustrates the company’s effort to develop therapies for solid metastatic tumors through targeted immunostimulation.
ATOR-1017: This immunostimulatory antibody is undergoing phase 1 clinical trials for the treatment of metastatic cancer. ATOR-1017 represents Alligator Bioscience’s commitment to advancing immunotherapy for cancer treatment.
Technology Platforms:
- ALLIGATOR-GOLD: A proprietary human antibody library, encompassing roughly 60 billion unique antibody fragments, enabling the discovery of novel cancer therapeutics.
- ALLIGATOR-FAB: Built on multiple scaffolds with optimal drug development properties, this platform increases the structural diversity of generated antibodies.
- FIND: A molecular evolution technology employed for the optimization of antibodies and other proteins, showcasing the company's prowess in evolutionary biotechnology.
- RUBY: A bispecific antibody format designed to enhance the effectiveness of immunotherapies by targeting multiple pathways.
Contact Information
